GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: Tominersen
DRUG: Placebo

Sponsor

Hoffmann-La Roche